Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9687368 | 1.00 | TSHR (0.47) | TSHRCYP2C9CYP2C19MAPK1CYP2D6 | |
| SCHEMBL13660514 | 0.84 | CHRNB2 (0.49) | CHRNA7LMNA | |
| SCHEMBL9688416 | 0.82 | TSHR (0.46) | TSHRCYP2C9CYP2C19MAPK1CYP2D6 | |
| SCHEMBL4296694 | 0.82 | TSHR (0.46) | TSHRCYP2C9CYP2C19MAPK1CYP2D6 | |
| SCHEMBL9688425 | 0.82 | TSHR (0.46) | TSHRCYP2C9CYP2C19MAPK1CYP2D6 | |
| SCHEMBL13660580 | 0.81 | ALDH1A1 (0.55) | TSHR | |
| SCHEMBL4290379 | 0.81 | HRH3 (0.51) | TSHRCYP2C9CYP2C19MAPK1CYP2D6 | |
| Hydrochloric Acid SCHEMBL9688480 | 0.81 | CYP19A1 (0.47) | TSHRCYP2C9CYP2C19MAPK1CYP2D6 | |
| SCHEMBL4290125 | 0.78 | HRH3 (0.58) | TSHRCYP2C9CYP2C19MAPK1CYP2D6 | |
| SCHEMBL4290121 | 0.78 | HRH3 (0.58) | TSHRCYP2C9CYP2C19MAPK1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0237169-B1 | 5-SUBSTITUTED OCTAHYDROINDOLIZINE ANALGESICS COMPOUNDS AND 7-KETO INTERMEDIATES | McNeilab, Inc. (US) | 1992-07-08 | — | — | EP | claimed |
| EP-0237169-A1 | 5-Substituted octahydroindolizine analgesics compounds and 7-keto intermediates | McNeilab, Inc. (US) | 1987-09-16 | — | — | EP | claimed |
| US-20090263322-A1 | OCTAHYDRO-INDOLIZINE AND QUINOLIZINE AND HEXAHYDRO-PYRROLIZINES | APODACA RICHARD | 2009-10-22 | — | — | US | disclosed |
| US-20090263322-A1 | OCTAHYDRO-INDOLIZINE AND QUINOLIZINE AND HEXAHYDRO-PYRROLIZINES | APODACA RICHARD | 2009-10-22 | — | — | US | disclosed |
| US-20090263322-A1 | OCTAHYDRO-INDOLIZINE AND QUINOLIZINE AND HEXAHYDRO-PYRROLIZINES | APODACA RICHARD | 2009-10-22 | — | — | US | disclosed |
| US-20050288323-A1 | Octahydro-indolizine and quinolizine and hexahydro-pyrrolizine | APODACA RICHARD | 2005-12-29 | — | — | US | disclosed |
| US-20040167336-A1 | Octahydro-indolizine and quinolizine and hexahydro-pyrrolizine | APODACA RICHARD (US) | 2004-08-26 | — | — | US | disclosed |
| EP-1326863-A2 | OCTAHYDRO-INDOLIZINES AND QUINOLIZINES AND HEXAHYDRO-PYRROLIZINES | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-07-16 | — | — | EP | disclosed |
| US-20030013733-A1 | Octahydro-indolizine and quinolizine and hexahydro-pyrrolizine | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2003-01-16 | — | — | US | disclosed |
| WO-2002024695-A2 | OCTAHYDRO-INDOLIZINES AND QUINOLIZINES AND HEXAHYDRO-PYRROLIZINES | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2002-03-28 | — | — | WO | disclosed |
| EP-0237169-B1 | 5-SUBSTITUTED OCTAHYDROINDOLIZINE ANALGESICS COMPOUNDS AND 7-KETO INTERMEDIATES | McNeilab, Inc. (US) | 1992-07-08 | — | — | EP | disclosed |
| EP-0237169-A1 | 5-Substituted octahydroindolizine analgesics compounds and 7-keto intermediates | McNeilab, Inc. (US) | 1987-09-16 | — | — | EP | disclosed |
| US-4689329-A | 5-substituted octahydroindolizine analgesics compounds and 7-keto intermediates | MCNEILAB, INC. (US) | 1987-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288323-A1 | Octahydro-indolizine and quinolizine and hexahydro-pyrrolizine | HRH4, HNMT, HRH1 | TSHR 2617/4885CYP2C9 937/4885CYP2C19 540/4885 |
| US-20030013733-A1 | Octahydro-indolizine and quinolizine and hexahydro-pyrrolizine | HRH4, HNMT, HRH1 | TSHR 2617/4885CYP2C9 937/4885CYP2C19 540/4885 |
| US-20040167336-A1 | Octahydro-indolizine and quinolizine and hexahydro-pyrrolizine | HRH4, HNMT, HRH1 | TSHR 2617/4885CYP2C9 937/4885CYP2C19 540/4885 |
| US-20090263322-A1 | OCTAHYDRO-INDOLIZINE AND QUINOLIZINE AND HEXAHYDRO-PYRROLIZINES | HRH4, HNMT, HRH1 | TSHR 2532/4885CYP2C9 946/4885CYP2C19 539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.